Press releases
Â鶹Æƽâ°æ strengthens its arsenal of hepatitis B potential therapies
Lyon, November 25, 2015 – Â鶹Æƽâ°æ, a biopharmaceutical company focused on developing treatments for acute and chronic viral infections, is announcing that it has obtained a license to a key patent enabling it to use agonists of the farnesoid X receptor (FXR) as hepatitis B treatments.
POXEL and Â鶹Æƽâ°æ Sign License Agreement on POXEL’s FXR Agonists Program
Lyon, France, May 6, 2015 – POXEL SA (Euronext: POXEL), a biopharmaceutical company developing innovative drugs to treat type 2 diabetes, and Â鶹Æƽâ°æS, a newly-formed company focused on the treatment of acute and chronic viral infections, today announced the signing of a license agreement under which ENYO will gain access to Poxel’s FXR (farnesoid X receptor) agonist compounds for infection-related indications with Poxel retaining rights regarding therapeutic indications centered on its core expertise.
